I think most of us are convinced about the science in terms of a high probability of success of BETonMACE.

There are many investors that are like me and are long for that exact reason. Others will hopefully make lots of money along the way through via their trading.

Big pharma seems to be completely absent from the seen regarding RVX and apabetalone. However, I have no way of knowing that they (BP) are not interested. Don has said they are in discussions with interested parties and this seems reasonable to me. It's not as if these people do not travel in the same circles.

So it's a bit like sitting back and watching the grass grow until 2018 and then back up the truck.

However many things will happen in between;

1. Don and his team achieved a rather strategically brilliant move this year with it's deal with Shenzen Hepalink.
2. This deal gives access to billions of patients in markets precisely where DM and CVD are growing at rapid rates.
3. This deal provides clinical trial partnership.
4. This deal gives access to the huge scientific knowledge pool of resources at Hepalink.
5. This deal gives production and downstream marketing and distribution to markets of billions.
6. As RVX adds new regional partners they are building a downstream production and distribution capability that effectively transforms Resverlogix into a fully integrated company from drug development through production, distribution and marketing. The cost for BP to buy this out will be an eye opener for them.

I sense there is an underlying momentum building on a few fronts;

• Growing interest and recognition of the power of epigenetics to transform the way people with chronic diseases, various cancers and rare diseases will receive treatment in the future.
• Growing interest within analysts to cover this drug and company.
• Growing interest in the financial community at large.
• Continued discovery by RVX on the MOA of rvx-208 (apabetalone).

We've discussed the other factors such as the orphan trial.

When we consider the fact that the patents on rvx-208 and in addition the patents on rvx-208 + rosuvastatin extend out to 2029 in many countries, as I recall, it should be a wake up call to BP and in particular Astra Zenica. But I guess we'll see. Who knows what is happening behind the scenes.

We have seen that BP has been testing CEPT inhibitors and only Merck is continuing their trial. As BDAZ pointed out Merck's product dramatically increased HDL (possibly non functional HDL) but the there is no evidence that it reduces MACE. Hence the reason for continuing their trial.

On the Zenith side I sort of feel it is perhaps where rvx-208 was 8 years ago. I don't know much about Zenith but it's genesis was with RVX and as such benefitted from the transition to epigenetics. Hence they are far advanced in terms of the science and may well have a lead but they are still starting in the agar plate as far as I know. So I have no idea about economics benefits as a shareholder of these illiquid shares.

Anyway, nothing new but I was just trying to shape my thoughts.

I'm very happy with the undervalued share price as I am moving into a period of accumulation.

GLTA DYODD

Toinv